<![CDATA[28 A Cost-Utility Analysis Comparing Indocyanine Green to Methylene Blue Dye in Axillary Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer]]>

Indocyanine GreenMethylene Blue DyePositive

AI Analysis

Summary

A cost-utility analysis comparing indocyanine green (ICG) to methylene blue for sentinel lymph node biopsy in breast cancer found ICG to be more cost-effective with an incremental cost-effectiveness ratio of $4,044/QALY and 80% probability of superiority in Monte Carlo simulation.

Importance:3/10

Sentiment:

0.60

health economicscost-utility analysisbreast cancersentinel lymph node biopsySLNBICER

Related Companies

$GPLB

Read the original article

Published by Cancer Network on July 3, 2026 10:30 PM

Read Original